Company news
BetterLife Pharma Inc. news in 2026
BetterLife Pharma Inc.'s news releases, calls and decks from 2026, newest first.
2026-11-05 BETR – Board Changes FINAL
November 5, 2026
BetterLife Pharma Appoints Henry Chow, CPA, CA, to Board of Directors
November 5, 2026
BetterLife Pharma Appoints LifeSci Advisors as Investor Relations Firm
October 27, 2026
BetterLife Pharma Appoints Professor Richard B. Lipton as Co-Chair of its Scientific Advisory Board
October 19, 2026
BetterLife Pharma Appoints Sheila Leitzinger as Head of Clinical Operations
October 15, 2026
BetterLife Pharma Establishes Scientific Advisory Board for Headache Program; Professor Peter Goadsby Appointed Co-Chair
October 14, 2026
BetterLife Pharma Addresses Notice of Civil Claim Filed by Steven Sangha
October 9, 2026
BetterLife Pharma Announces Rescheduling and Reclassification of Annual General Meeting to Annual General and Special Meeting
September 29, 2026
BetterLife Pharma Inc. Announces Closing of US$100 Million Public Offering of Common Shares and Pre-Funded Warrants
September 17, 2026
BetterLife Pharma Inc. Announces Filing of Final Prospectus for US$100 Million Public Offering of Common Shares and Pre-Funded Warrants
September 11, 2026
BetterLife Pharma Appoints Charles Duncan as Director and Chair of the Audit Committee
August 31, 2026
BetterLife Pharma Inc. Announces Pricing of US$100 Million Public Offering of Common Shares and Pre-Funded Warrants
August 28, 2026
BetterLife Pharma Inc. Announces Proposed Public Offering of Common Shares and Pre-Funded Warrants
August 24, 2026
BetterLife Pharma Appoints Mahan Chehrenama, DO, as Chief Medical Officer
August 19, 2026
BetterLife Pharma Prioritizes BETR-001 to Lead in Migraine and Headache Disorders, Targeting a Clinically Validated, FDA-Precedented Serotonergic Mechanism
July 13, 2026
BetterLife Pharma Announces Appointment of John W. LaRocca to Board of Directors and Audit Committee
July 9, 2026
BetterLife Engages Nucro-Technics to Complete the last GLP Toxicology Study of BETR-001 Required by the FDA for IND and Phase 1
July 6, 2026
BetterLife Engages Syner-G to Oversee GMP Manufacturing of BETR-001 for IND and Phase 1
June 25, 2026
BetterLife Pharma Secures CAD $2 Million in New Capital to Complete BETR-001 FDA IND Filing
June 22, 2026
Annual Report for Fiscal Year Ending January 31, 2026 (Form 20-F)
June 1, 2026
BetterLife Pharma Announces Appointment of Doug Drysdale as Executive Chairman and Director
May 13, 2026
BetterLife Pharma to Participate in YAFO Capital Access Asia Partnering Forum During JPM Week in San Francisco
January 6, 2026
Decks in 2026
- Investor Presentation (July 2026)
Investor deck · 18 slides · July 2026